Key clinical point: Administering CPX-351 prior to a three-drug regimen produced a high response rate in pediatric patients with acute myeloid leukemia in first relapse.
Major finding: CPX-351 followed by fludarabine, cytarabine, and filgrastim produced an overall response rate of 81%.
Study details: Phase 1/2 trial of 38 patients.
Disclosures: The trial was sponsored by the Children’s Oncology Group in collaboration with the National Cancer Institute. The speaker disclosed relationships with Juno Therapeutics and Celgene.
Cooper TM et al. ASCO 2019. Abstract 10003.